Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo

Human EGF Receptor 2 (HER2) is an important oncogene driving aggressive metastatic growth in up to 20% of breast cancer tumors. At the same time, it presents a target for passive immunotherapy such as trastuzumab (TZM). Although TZM has been widely used clinically since 1998, not all eligible patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudkouskaya, Alena, Smith, Jason T., Intes, Xavier, Barroso, Margarida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767145/
https://www.ncbi.nlm.nih.gov/pubmed/33348564
http://dx.doi.org/10.3390/molecules25245976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767145/
https://www.ncbi.nlm.nih.gov/pubmed/33348564
http://dx.doi.org/10.3390/molecules25245976

Ejemplares similares